Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
PLOS Glob Public Health ; 3(4): e0000946, 2023.
Article in English | MEDLINE | ID: covidwho-2302217

ABSTRACT

India experienced the second wave of SARS-CoV-2 infection from April 3 to June 10, 2021. During the second wave, Delta variant B.1617.2 emerged as the predominant strain, spiking cases from 12.5 million to 29.3 million (cumulative) by the end of the surge in India. Vaccines against COVID-19 are a potent tool to control and end the pandemic in addition to other control measures. India rolled out its vaccination programme on January 16, 2021, initially with two vaccines that were given emergency authorization-Covaxin (BBV152) and Covishield (ChAdOx1 nCoV- 19). Vaccination was initially started for the elderly (60+) and front-line workers and then gradually opened to different age groups. The second wave hit when vaccination was picking up pace in India. There were instances of vaccinated people (fully and partially) getting infected, and reinfections were also reported. We undertook a survey of staff (front line health care workers and supporting) of 15 medical colleges and research institutes across India to assess the vaccination coverage, incidence of breakthrough infections, and reinfections among them from June 2 to July 10, 2021. A total of 1876 staff participated, and 1484 forms were selected for analysis after removing duplicates and erroneous entries (n = 392). We found that among the respondents at the time of response, 17.6% were unvaccinated, 19.8% were partially vaccinated (received the first dose), and 62.5% were fully vaccinated (received both doses). Incidence of breakthrough infections was 8.7% among the 801 individuals (70/801) tested at least 14 days after the 2nd dose of vaccine. Eight participants reported reinfection in the overall infected group and reinfection incidence rate was 5.1%. Out of (N = 349) infected individuals 243 (69.6%) were unvaccinated and 106 (30.3%) were vaccinated. Our findings reveal the protective effect of vaccination and its role as an essential tool in the struggle against this pandemic.

3.
Public Health Pract (Oxf) ; 2: 100167, 2021 Nov.
Article in English | MEDLINE | ID: covidwho-1358299

ABSTRACT

Healthcare systems in resource scarce countries continue to face unprecedented challenges due to the COVID-19 pandemic, including saturation of healthcare system capacities. Data suggest that medical staff deployed for COVID-19 containment are at higher risk of exposure and thus greater susceptibility to infection, further decreasing the available workforce. Telemedicine, as an additional healthcare delivery approach, can circumvent hospital visits of non-critical COVID-19 patients and thus reduce exposure of both providers and non-COVID-19 patients. Widespread implementation of telemedicine at this watershed moment for healthcare system in India will establish a new public health delivery alternative that can cater to the COVID-19 pandemic and beyond.

5.
Open Biol ; 11(6): 200288, 2021 06.
Article in English | MEDLINE | ID: covidwho-1249358

ABSTRACT

We describe the epidemiological characteristics and associated risk factors of those presenting at a large testing centre for SARS-CoV-2 infection. This is a retrospective record review of individuals who underwent SARS-CoV-2 testing by reverse transcription-polymerase chain reaction (RT-PCR) at a high-throughput national-level government facility located in the north of India. Samples collected from 6 April to 31 December 2020 are included in this work and represent four highly populous regions. Additionally, there was a prospective follow-up of 1729 cases through telephone interviews from 25 May 2020 to 20 June 2020. Descriptive analysis has been performed for profiling clinic-epidemiological aspects of suspect cases. Multivariable logistic regression analysis was undertaken to determine risk factors that are associated with SARS-CoV-2 test positivity and symptom status. A total of 125 600 participants' details have been included in this report. The mean (s.d.) age of the participants was 33.1 (±15.3) years and 66% were male. Among these tested, 9515 (7.6%) were positive for COVID-19. A large proportion of positive cases were asymptomatic. In symptomatic positive cases, the commonest symptoms were cough and fever. Increasing age (groups 20-59 and ≥60 years compared to age group less than 5 years), male sex, history of international travel, symptoms for SARS-CoV-2, and participants from Delhi and Madhya Pradesh were positively associated with SARS-CoV-2 test positivity. Having co-morbidity, risk behaviours and intra-familial positivity were associated with a positive odds ratio for exhibiting SARS-CoV-2 symptoms. Intensified testing and isolation of cases, identification of both asymptomatic and symptomatic individuals and additional care of those with co-morbidities and risk behaviours will all be collectively important for disease containment in India. Reasons for differentials in testing between men and women remain an important area for in-depth study. The increased deployment of vaccines is likely to impact the trajectory of COVID-19 in the coming time, and therefore our data will serve as a comparative resource as India experiences the second wave of infection in light of newer variants that are likely to accelerate disease spread.


Subject(s)
COVID-19 Nucleic Acid Testing/statistics & numerical data , COVID-19/epidemiology , Adolescent , Adult , Age Factors , Aged , Comorbidity , Female , Humans , India , Male , Middle Aged , Risk Factors , Sex Factors , Travel/statistics & numerical data
6.
Trans R Soc Trop Med Hyg ; 115(1): 6-8, 2021 01 07.
Article in English | MEDLINE | ID: covidwho-1066408

ABSTRACT

To counter the coronavirus disease 2019 (COVID-19) pandemic, each country must design sustainable control plans given the inherent disparities in wealth and healthcare systems. Most malaria-endemic countries run well-entrenched malaria control programs via their established frameworks for diagnosis, case management, treatment and overall surveillance. We propose that the malaria control infrastructures can be partially co-opted for launching sustainable COVID-19 mitigation plans.


Subject(s)
COVID-19/prevention & control , Delivery of Health Care , Health Planning , Malaria/prevention & control , Pandemics , COVID-19/epidemiology , Endemic Diseases , Government Programs , Humans , SARS-CoV-2
7.
Am J Trop Med Hyg ; 103(1): 28-30, 2020 07.
Article in English | MEDLINE | ID: covidwho-646847

ABSTRACT

Most countries around the world have responded promptly to the novel coronavirus disease (COVID-19) challenge by adopting considered and scientifically guided strategies for its containment. However, the situation is more complex for nations where malaria is endemic, as they now have the additional burden of COVID-19. In such nations, the healthcare systems are either in the preparatory or containment phase of the current pandemic. This enforced, sudden, and sharp public health refocus is likely to result in the disruption of annual malaria control activities such as distribution of insecticide-impregnated bed nets, indoor residual spraying of insecticide, maintenance of malaria surveillance, and mass provision of antimalarial drugs. Nonetheless, we feel that the best facets of COVID-19 public health management can become new guiding principles in malaria-endemic countries to improve malaria control and hasten malaria elimination. Redirection against malaria of the best public health initiatives used in COVID-19 containment could fast-track the global goal of a malaria-free world. Such public health advancement could be one positive outcome from the scourge of COVID-19.


Subject(s)
Coronavirus Infections/prevention & control , Malaria/prevention & control , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Population Health Management , Betacoronavirus , Biomedical Technology , COVID-19 , Community Participation , Epidemiological Monitoring , Humans , Leadership , Mosquito Control , Public-Private Sector Partnerships , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL